Product Name: CellCept [mycophenolate mofetil]
Date of Report: To be Published
Phase: IV
A Study of CellCept (Mycophenolate Mofetil) and Zenapax in Prevention of Acute Rejection in Heart Transplant Patients
Product Name: CellCept [mycophenolate mofetil]
Date of Report: To be Published
Phase: III
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: 8/1/2006
Phase: IV
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune®) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: 4/2/2007
Phase: II
An open, pilot, parallel group, randomized clinical trial to evaluate pharmacokinetic variability of mycophenolate mofetil in association with cyclosporine and corticosteriods administered for 9 months following a dose controlled or a concentration controlled 3 months regimen in primary orthotopic heart transplant recipients.
Product Name: Zenapax [daclizumab]
Date of Report: 3/21/2003
Phase: IV
A double-blind, placebo-controlled, randomized study to assess the efficacy and safety of Zenapax in combination with CellCept, cyclosporine, and corticosteroids in patients undergoing cardiac transplantation
